Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections
Document Type
Article
Publication Title
Clinical Infectious Diseases
Abstract
Vancomycin remains the reference standard for the treatment of systemic infection caused by methicillin-resistant Staphylococcus aureus (MRSA). However, as a result of limited tissue distribution, as well as the emergence of isolates with reduced susceptibility and in vitro resistance to vancomycin, the need for alternative therapies that target MRSA has become apparent. New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim. The present article will review clinical issues surrounding the newly marketed and investigational agents with activity against MRSA. © 2007 by the Infectious Diseases Society of America. All rights reserved.
DOI
10.1086/519471
Publication Date
9-15-2007
Recommended Citation
Micek, Scott T., "Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections" (2007). Pharmacy Practice Faculty Publications. 159.
https://doi.org/10.1086/519471
https://collections.uhsp.edu/pharm-practice_pubs/159